文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

寡转移性肾细胞癌立体定向放疗与手术转移灶切除的总生存比较

Overall survival after stereotactic radiotherapy or surgical metastasectomy in oligometastatic renal cell carcinoma patients treated at two Swedish centres 2005-2014.
PubMed 文献 · Radiother Oncol · 2018-05-10

该回顾性研究纳入2005-2014年瑞典两个肿瘤中心接受立体定向放疗(SRT)、手术转移灶切除(SM)或两者序贯治疗的117例转移性肾细胞癌(mRCC)患者,中位随访63个月。SRT与SM的总生存(中位51个月)无显著差异;ECOG 1 vs 0、颅内靶灶和治疗前观察等待>18个月与总生存独立相关。

要点

  • SRT与SM的总生存无显著差异,中位OS均为51个月。
  • ECOG 1 vs 0、颅内靶灶和治疗前观察等待>18个月与OS独立相关。
  • 15%的根治性治疗患者(n=60)在中位随访87个月时无复发。

核心结论

  • 在靶向治疗时代,寡转移性mRCC患者接受SRT的总生存与SM相当。
  • 体能状态好、非脑转移且初始观察等待>18个月的患者预后最佳。

研究设计与样本

  • 回顾性纳入2005-2014年瑞典两个肿瘤中心的117例mRCC患者,接受SRT(n=57)、SM(n=30)或两者序贯(n=30),中位随访63个月。

主要发现

  • SRT与SM的中位OS均为51个月,无显著差异。
  • 15%的根治性治疗患者(n=60)在中位随访87个月时无复发。

临床怎么用

  • 对于寡转移性mRCC,SRT可作为SM的替代选择,尤其适合不利风险特征常见的患者。
  • 体能状态好、非脑转移且经过初始观察等待的患者可能从局部治疗中获益最大。

局限性

  • 回顾性研究设计,SRT患者更可能具有不利风险特征,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Investigate effects of stereotactic radiotherapy (SRT) or surgical metastasectomy (SM) on overall survival (OS) in metastatic renal cell carcinoma (mRCC) in the era of targeted agents (TA). MATERIAL AND METHODS: mRCC patients (n = 117) treated with SRT (n = 57), SM (n = 30) or both modalities sequentially (n = 30) at two oncological centres in Sweden in 2005-2014 were retrospectively included. Median follow-up (mFU) was 63 months. RESULTS: A majority had clear cell histology, 1-3 metastases, and ECOG performance status of 0 or 1. Two thirds had intermediate or poor risk and 44% synchronous metastases. 65% received TA. SRT patients were more likely to have adverse risk profiles. Median OS was 51 months without significant differences between SRT and SM. ECOG 1 vs 0 (HR 2.9; CI 1.6-5.2; p < 0.001), intracranial targets (HR 1.8; CI 1.1-3.2; p = 0.03) and watchful waiting >18 months prior to treatment (HR 0.3; CI 0.2-0.6; p = 0.001) were independently associated with OS. 15% of curatively treated patients (n = 60) were relapse-free with mFU of 87 months. CONCLUSIONS: OS after SRT was comparable to SM and longer than expected considering patients with adverse risk profiles were common. Fit patients with non-brain metastases treated after an initial period of watchful waiting had the best prognosis.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Stenman M, Sinclair G, Paavola P, et al. Overall survival after stereotactic radiotherapy or surgical metastasectomy in oligometastatic renal cell carcinoma patients treated at two Swedish centres 2005-2014. Radiother Oncol. 2018. PMID: 29754859. doi:10.1016/j.radonc.2018.04.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。